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Abstract
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) 
characterized by autoimmune mediated demyelination and neurodegeneration. The CNS of 
patients with MS harbors expanded clones of antigen-experienced B cells that reside in distinct 
compartments including the meninges, cerebrospinal fluid (CSF) and parenchyma. It is not 
understood whether this immune infiltrate initiates its development in the CNS or in peripheral 
tissues. B cells in the CSF can exchange with those in peripheral blood, implying that CNS B cells 
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may have access to lymphoid tissue that may be the specific compartment(s) in which CNS 
resident B cells encounter antigen and experience affinity maturation. In this study, paired tissues 
were used to determine whether the B cells that populate the CNS mature in the draining cervical 
lymph nodes (CLNs). High-throughput sequencing of the antibody repertoire demonstrated that 
clonally expanded B cells were present in both compartments. Founding members of clonal 
families were more often found in the draining CLNs. More mature clonal family members 
derived from these founders were observed in the draining CLNs and also in the CNS, including 
lesions. These data provide new evidence that B cells traffic freely across the tissue barrier with 
the majority of B cell maturation occurring outside of the CNS in the secondary lymphoid tissue. 
Our study may aid in further defining the mechanisms of immunomodulatory therapies that either 
deplete circulating B cells or impact the intrathecal B cell compartment by inhibiting lymphocyte 
transmigration into the CNS.
Introduction
Multiple sclerosis (MS) is a multifocal demyelinating disease caused by an autoimmune 
response in genetically susceptible individuals (1). While animal models of autoimmunity 
have long suggested a critical role for T cells in disease pathogenesis, it has become clear 
that the autoimmune response is mediated by a number of cell types. B cells in particular 
appear to be of fundamental importance in MS (2). B cell subsets participate in the 
production of the hallmark MS cerebrospinal fluid (CSF) oligoclonal bands (OCB) and more 
recent seminal findings, which implicate B cells in the disease, include B cell clustering both 
at the site of central nervous system (CNS) tissue injury (3) and the meninges (4). 
Furthermore, several MS autoantibody specificities (5, 6) have recently been reported. B cell 
depletion has emerged as a beneficial therapeutic approach for MS (7). The ENCODE study 
(8) implicated B cells second only to T cells among the cell types affected by MS 
susceptibility genes. Finally, their role as both effective antigen-presenting cells and immune 
response regulators (9) in autoimmunity has been reported.
Within the CNS of patients with MS, B cells can be observed in distinct compartments 
including white matter lesions, the normal appearing white matter, the cortex, the CSF and 
the meninges (10, 11). B cells found in the meninges often organize into structures 
resembling those found in lymphoid tissue (4, 12). The B cells that populate these distinct 
compartments of the CNS form a network of clonally related cells (10). Intraclonal variants, 
that represent steps in the antigen-driven affinity maturation process, are also present in MS 
CNS compartments (10, 13). OCB are produced, at least in part, by these resident B cell 
clones (14). Furthermore, it is now appreciated that B cell clones present in the CSF are also 
represented in the blood (15) and that IgG representing the OCB are linked to circulating 
peripheral B cells (16).
Although many characteristics of the B cells populating the CNS are now understood, it is 
not known whether these B cells experience maturation outside of the CNS then traffic 
within the brain or whether the process is exclusively confined within the CNS. A further 
understanding of this process would help clarify whether MS is primarily a disease of the 
CNS or whether lymphocytes activated in the peripheral immune system drive the disease. 
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This is of particular importance considering that some of the most effective MS therapies 
either deplete circulating B cells (anti-CD20; rituximab, ocrelizumab, ofatumumab) or 
impact the intrathecal B cell compartment by inhibiting lymphocyte transmigration into the 
CNS (anti-VLA4; natalizumab)
We reasoned that CNS B cells in patients with MS may gain antigen experience and mature 
in lymph nodes associated with the CNS, namely the CLNs that drain the brain tissue. Both 
neuronal and myelin-derived antigens are present in the draining CLNs (17, 18). This 
suggests that immune responses in the CNS can be organized and/or initiated in the 
periphery and implicates the CLNs among the anatomical sites at which such responses 
materialize. In support of this, surgical removal of cervical and lumbar lymph nodes reduces 
relapse burden in the commonly used model for MS, experimental autoimmune 
encephalomyelitis (EAE) (17).
B cell antibody repertoires from a series of paired tissues representing both the CNS and 
secondary lymphoid organs were constructed so that we could identify and re-construct B 
cell lineages across tissues. Founding members of clonal families were more often found in 
the draining CLNs, while more mature members derived from these founders were observed 
both in the draining CLNs and the CNS. These data provide new evidence that B cells traffic 
freely across the tissue barrier, with the majority of B cell maturation occurring outside of 
the CNS in the draining secondary lymphoid tissue.
Results
Characterization of tissue specimens
We studied the B cell antibody repertoire of both CNS-derived and secondary lymphoid 
tissue (draining CLNs) in autopsy tissue derived from five subjects with MS (Table 1). The 
brain parenchyma was evaluated by immunohistochemistry to confirm the presence of 
demyelinated white matter lesions and immune infiltrates. None of the lesions exhibited 
active demyelination as characterized by the presence of myelin phagocytosing 
macrophages. However, the lesions contained varying degrees of microglial activation 
(CD68+) and perivascular infiltrations including B cells (CD20+), T cells (CD3+) and 
monocytes (CD68+) (fig. S3). CD138+ plasma cells, which often accompany B cells in MS 
lesions (19), were not observed.
Related B cells populate the CNS and secondary lymphoid tissue compartments
To explore whether the CNS and peripheral tissues harbored B cells that were related to one 
another, we initially performed conventional Sanger sequencing of variable region heavy 
chain and variable region light chain antibody repertoires from serially sectioned tissue 
specimens from subject M1. We obtained approximately 1,300 sequence reads, which 
reduced to 754 sequences used for analysis when PCR generated repeats were removed. We 
identified a total of 9 clonal lineages populating both the CNS and peripheral secondary 
lymphoid tissue using this low-throughput approach (fig. S4).
We then applied high-throughput, next-generation sequencing to an additional cohort of 
specimens to validate our observations, provide a broader examination of the MS B cell 
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repertoire that spans the periphery and CNS, and determine the pattern of B cell traffic 
across the blood brain barrier (BBB). Eleven tissue specimens from four subjects (M2 to 
M5) were serially sectioned and each divided into two or three independent heavy chain 
repertories. Approximately 32 million total raw sequence reads were collected from the 32 
separate repertoires. Quality control processing and selecting unique reads that each 
represent a single mRNA molecule reduced the data to approximately 550,000 high fidelity 
sequences for analysis (table S2). Sequences derived from subject M4 were not included in 
subsequent analysis because the number of filtered unique sequences derived from the lesion 
was too low to provide meaningful interpretation.
In subjects M2, M3 and M5, we found that members of clones (and clonal variants) resided 
in the secondary lymphoid tissue and CNS compartments, including lesions, choroid plexus 
and pia mater (Fig. 1A). Representative alignments of clones, including intraclonal variants 
that populated distinct compartments are shown in fig. S5. The fraction of sequences shared 
between the CNS tissue and draining CLNs was unambiguous. For example, 12.5% of the 
individual B cell IgG sequences in the lesion tissue from subject M5 were also represented 
in one CLN (CLN-A) and 15.3% in the other (CLN-B). Similarly, 6.7% and 7.6% of the 
individual B cell IgG sequences in the lesion were also represented in the CLNs of subjects 
M2 and M3, respectively. We also applied this analysis to sequences derived from different 
subjects. The mean sequence overlap was 0.36% for IgG, 0.06% for IgM and 0.1% for IgA, 
further highlighting the significance of the overlap we found between the CNS and CLNs. In 
subjects M3 and M5 the vast majority of the sequences from clones that included CNS 
members resided in the CLNs (Fig. 1B). In subject M2 this distribution was not as apparent 
because the total number of multi-compartment clones was lower than that of M3 and M5.
The CNS B cell repertoire is populated with antigen-experienced cells
In agreement with previous reports (10, 13, 20, 21), the MS CNS B cells were characteristic 
of a post-germinal center reaction in that most had class switched, acquired somatic 
mutations and expanded clonally; all of which are representative of antigen-driven selection. 
The isotype distribution (table S3) in the CNS from each of the four subjects was 
predominated by IgG. A fraction belonged to the IgM isotype and each lesion included a 
noticeable fraction of IgA ranging from 3%–13%. The isotype distribution in the choroid 
plexus specimen from subject M5 was 72%, 5% and 23% IgG, IgM and IgA respectively. 
CLNs expectedly included all three isotypes with IgG or IgM preferentially distributed.
The accumulation of somatic mutations was also evident. The mutation frequency in the 
sequences (number of nucleotide and amino acid mutations accumulated per Ig sequence) 
was similar in the distinct CNS compartments and the CLNs. This finding was consistent in 
sequences belonging to clones with multiple members (fig. S6A) and singletons (fig. S6B). 
The quantity of mutations was consistent with the antigen experience of mature B cell 
populations observed in other settings (22, 23). To further confirm that the CNS B cells were 
antigen driven, we employed an algorithm (BASELINe) that quantifies selection by 
analyzing mutation patterns in experimentally derived immunoglobulin sequences (24). This 
analysis showed evidence of negative selection in the framework regions and positive 
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selection in the complementary determining regions (fig. S7), which are both characteristics 
that are consistent with affinity-matured B cells.
Further highlighting the antigen experience of the CNS repertoire, the majority of B cells 
were distributed into clonal families (Table 2). Both the CLNs and CNS compartments 
included clonally expanded B cells with many representing more than half of all the B cells. 
While the class-switched IgG and IgA isotypes most often represent antigen experienced B 
cells, the IgM isotype can represent either naïve B cells or a population of non-switched, 
experienced memory cells. We found that IgM sequences were often parts of clonal groups 
with noticeable evidence of expansion (Table 2). We next examined the mutational load that 
the IgM sequences carried. IgM sequences that were not part of expanded clones had 
considerably fewer mutations than those belonging to expanded clones (Fig. S6), suggesting 
that both switched and non-switched memory B cells populate the MS CNS.
The CNS and lymphoid B cell repertoires are distinct
Given that we found considerable overlap between the repertoire in the CNS and the 
periphery we sought to determine whether the sequences from each compartment displayed 
unique features. We first assessed immunoglobulin heavy chain variable (IGHV) family and 
immunoglobulin heavy chain joining (IGHJ) gene usage by calculating odds ratios for each 
gene segment based on the entire repertoire from each subject. This analysis showed that 
particular IGHV families and IGHJ genes were found more often than expected in the CNS, 
and in other instances less frequently than expected (Fig. 2A and 2B). Disproportionate 
IGHV family usage has been observed in MS CNS/CSF-derived sequence libraries; the 
IGHV4 family is particularly overrepresented (25, 26). We did find IGHV4 family members 
enriched in the CNS relative to the CLN of M3 and M5, but not M2 (Fig. 2A, S8 and S9). 
The usage of IGHJ genes (Fig. 2B and S10) was heavily biased toward IGHJ4 in the both 
the CNS and CLNs. The overuse of IGHJ4 is consistent with other reports of such bias in 
the CNS of patients with MS (21) and circulation of healthy individuals (27), and as such 
was not a distinguishing characteristic of MS-associated B cells.
Although it is certain that the repertoires of distinct compartments overlap, many clones 
were present only in a single compartment. The B cell repertoire in the CNS was more 
focused compared to the CLN (Fig. 2C), both in terms of fewer total clones (q=0) and less 
dominance by larger clones (q>1). Overall, these results indicate that the B cell repertoire is 
shared between these distinct compartments, but that each compartment has exclusive 
features.
Mature B cells traffic between the CNS and secondary lymphoid tissue
To gain further insight into how the individual products of affinity maturation were 
distributed between all of the tissue compartments, lineage trees of the clones were 
constructed. These trees (Fig. 3) indicate that the members of the different clones trafficked 
between the CNS and periphery. Both less mature and more experienced offspring were 
observed in the CNS and secondary lymphoid organs. This suggests that the products of B 
cell maturation steps are not restricted to a single compartment, but rather circulate during 
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the process, with the possible implication that clonal expansion of B cells occurs in multiple 
compartments.
Ancestral clonal family members reside in multiple compartments
Given that we found clones carrying evidence of affinity maturation in both the periphery 
and CNS, we next examined whether we could determine the direction of the traffic flow by 
examining the steps of the maturation process in distinct compartments. The lineage trees 
from expanded clones (>10 unique sequences) that included sequences from the CNS 
compartment (39 trees for M2, 335 trees for M3 and 1516 trees for M5) were collectively 
examined to determine the mutation profiles of B cells that populated multiple or single 
compartments. By analyzing the topology of the lineage trees, we found that B cells that 
resided in a single compartment tended to have maturation profiles with fewer downstream 
mutations than those that were found in multiple tissues (Fig. 4A), whereas B cells found in 
both the CNS and CLN demonstrated a propensity to give rise to multiple immediate 
daughter cells. That is, when considering B cell clonal populations that span multiple 
compartments, B cells that resided in both the CNS and CLN behaved as ancestors (i.e., they 
tended to produce progeny that undergo further rounds of somatic hypermutation). 
Conversely, their counterparts residing in a single tissue compartment often represent 
terminal nodes of the lineage tree (i.e., any progeny did not accumulate additional 
mutations). Fig. 4B further illustrates the ancestral character of multi-compartment B cells 
by showing that these B cells are more likely to be observed as ancestors than expected by 
chance. Taken together, this implies that local expansion of B cell populations regularly 
occurs following trafficking between compartments.
Clonal lineages that span multiple compartments likely originate in lymphoid tissue
In order to determine the origin site of multi-compartment B cell clones, we analyzed the 
distribution of founder compartments. For each lineage tree that contained both CNS and 
CLN sequences, the founder compartment was defined by the node(s) with the fewest 
number of mutational events (i.e., appearing closest to the germline sequence). We found 
that multi-compartment B cells, despite their low abundance (2.7 to 3.7% of sequences), 
were commonly founders (18.7% to 45.0% of founders), with statistically significant 
enrichment of founder occurrence at p<3.7×10−5 for all three subjects combined (Table 3). 
As the origin of multi-compartment B cells is ambiguous, we then looked at only the trees 
with founders that could be unambiguously assigned to a single-compartment. We observed 
that the majority of such founders were from the CLN (87.6% to 93.9% of single-
compartment founders), and that the observed number of CLN founders was greater than 
expected by chance (taking into consideration the fact that the majority of sequences are 
CLN) with statistically significant enrichment at p<4.3×10−5 for all three subjects combined 
(Table 3). While many founders were highly mutated, 18 lineage trees contained single-
compartment founders that carried unmutated IGHV/J segments (all from subject M5, 
shown in fig. S11). In every such lineage tree, the unmutated founder was derived from the 
CLN (Table 3). Overall, these data provide evidence for a peripheral origin of the expanded 
clones found on both sides of the BBB.
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A proposed model describing B cell population of the CNS
Antigen-experienced, clonally expanded B cells reside in both the CNS and secondary 
lymphoid organs (Fig. 5 and S12). The products of B cell antigen-driven affinity maturation 
traffic between the CNS and draining secondary lymphoid tissue through an ongoing 
dynamic process. B cells actively experiencing affinity maturation traffic between the 
draining CLNs and CNS compartments. Clonal family members, that represent the more 
evolved products of maturation, are more stationary as their residence is restricted to single 
compartments. However, less mature products (founders or ancestors) are shared between 
multiple compartments and more often originate in the peripheral lymphoid tissue. This 
model proposes that B cell maturation is not confined to the MS CNS, but occurs in both the 
periphery and CNS and further proposes that antigen-driven maturation originates in the 
periphery.
Discussion
The CNS of patients with MS harbors expanded clones of antigen-experienced B cells that 
reside in distinct compartments including the meninges, CSF and parenchyma. It remains 
unclear where MS CNS B cells encounter antigen and develop the characteristics that 
accompany post-germinal center experience. We address this fundamental question 
regarding the mechanism of B cell maturation and trafficking in the MS CNS. We have 
defined both the characteristics of B cells populating the MS CNS and their relationship to 
the secondary lymphoid organs. B cells residing in the MS CNS are largely antigen 
experienced as they display the principal characteristics of mature effector B cells. Members 
of these clones are not confined exclusively to the CNS but also occupy secondary lymphoid 
organs, which directly drain the CNS. Furthermore, these multi-compartment clonal 
members appear to circulate between the CNS and periphery, with the majority of parental 
clones arising in the periphery. These data collectively suggest that in the MS CNS B cells 
encounter antigen and gain experience in secondary lymphoid tissue. These B cells then 
dispatch colonists that populate the CNS then continue trafficking between the CNS and 
periphery. Although our data implicate peripheral compartments as the initial site for the 
majority of B cell maturation we do not exclude that maturation may continue to occur 
within the CNS. B cells populating the meninges often form organized structures that 
emulate germinal centers present in lymph nodes (3, 4, 12). It is conceivable that such 
structures are those in which CNS resident B cells encounter antigen and mature. Rare tissue 
collections that include these structures, paired with both lesions containing B cells and 
peripheral lymphoid tissues present an ideal setting for the study of their contribution.
Much of our previous work and that of others have relied on autopsy tissue (4, 10, 28) for 
the examination of immune cell infiltrates in MS CNS tissue. Biopsy tissue from living 
patients is rarely acquired and the small size of tissue considerably limits investigations. 
Historical archives include fixed tissue rather than fresh frozen. Contemporary deep 
sequencing approaches cannot be reliably performed using fixed tissue. Fresh frozen 
autopsy tissue is typically derived from older individuals with an advanced and progressive 
form of MS. Given that the repertoires here were constructed from autopsy-derived tissue, 
we were not able to assign sequence data to particular B cell phenotypes. Such approaches 
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would be possible through flow cytometry-based sorting of fresh samples prior to 
sequencing. We are limited from extending the interpretation of our data to all types of MS 
given that the majority of our tissue was derived from subjects in the progressive stage. 
However, we did include a single case of relapsing remitting MS (RRMS) in a younger 
subject. Furthermore, a recent study (15) demonstrated that the CSF B cell population is 
linked to B cells in the peripheral blood in younger patients with early RRMS. This study 
and ours taken together indicate that B cell traffic, both in and out of the CNS, can occur 
both at early and later stages of the disease. While the multi-compartment clonal lineages 
provide clear evidence that the clonally expanded B cells that populate the CNS are related 
to B cells in the peripheral lymphoid tissue, the conclusions concerning the directionality of 
B cell trafficking are based on a statistically significant enrichment. Direct proof for the 
model proposed herein would require in-vivo tracking of individual B cells in humans, 
which cannot be performed with current technology.
The role of B cells in the MS CNS
It is not entirely clear how B cells contribute to MS pathology. The major effector function 
of B cells includes antibody production, antigen presentation to T cells, and cytokine 
production. B cells can express pro-inflammatory cytokines such as interleukin (IL)-6, 
IL-12, tumor necrosis factor (TNF) and lymphotoxin and can perform an anti-inflammatory 
regulatory role through expression of IL-10 (29). In the context of the MS CNS, it is not 
known whether they function as antigen presenting cells (APC) or produce pro- or anti-
inflammatory cytokines. Moreover, it is not entirely clear how B cell subsets populate the 
MS CNS. Memory B cells are present, and they share the space with plasmablasts and 
plasma cells. Naïve cells, based on collective antibody sequencing repertories, appear to be a 
very minor fraction.
It has been clearly demonstrated that B cells present in MS tissue and CSF contribute to 
production of antibody (14, 30). While these antibodies may be disease related and 
participate in the autoimmune pathology, their antigen specificity has not been clearly 
demonstrated. A number of groups, including our own, continue to search for the antigens 
that may drive these B cells. Use of recombinant IgG derived from CNS resident B cell 
clones (31–33) and CSF-derived IgG (34, 35) both represent pragmatic approaches. The 
possibility remains that these CNS B cells are not specific for a single antigen. They may be 
targeting numerous antigens exposed during tissue injury. B cells accumulate in solid tumors 
and autoimmune tissue, including the MS meninges where they often organize as clusters 
termed tertiary lymphoid structures. The characteristics, such as the accumulation of 
antigen-experienced B cells, are shared between these different autoimmune tissue 
compartments and tumors. Those in tumors (23) are strikingly similar to those in the 
damaged muscle tissue of patients with myositis (36) and the joints of individuals with 
Lyme arthritis (37). One explanation for this activity is that antibodies are locally produced 
in response to tissue damage that occurs throughout the disease course. That is, the 
persistent B cell infiltration perhaps reflects the ongoing nature of tissue injury in MS and a 
chronic immune response to such injured tissue. Interestingly, both our group and others 
report the presence of numerous intraclonal variants (10, 13–15, 21, 30) indicating the 
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persistence of an ongoing process of affinity maturation, rather than the presence of a more 
final products, fully mature antibodies.
Some parallels to acute CNS inflammation such as that seen in viral encephalitis can be 
drawn. In those instances OCB that recognize a viral insult (38) are produced and B cell 
infiltrates have characteristics identical to those in the MS CNS (39). However, when the 
insult is cleared, the active immune response reflected by the OCB, disperses. Conversely, in 
MS it appears to remain in a chronically evolving, active state. It is possible that this is the 
product of a chronic infection. The actively replicating human virome that is held in-check 
by a normally functioning immune system (40) is still likely to provoke B cell responses. It 
is possible that a non-MS antigen-specific response may be the target of the CNS infiltrating 
B cells. Supporting this possibility is the conspicuous proportion of IgA-producing B cells 
we found, which suggests that the response may be linked to an exogenous microbial 
antigen. Using the recombinant immunoglobulin from the expanded CNS B cell clones 
along with innovative antigen screening technology, which should include post-translational 
modifications, non-protein entities such as lipids and high-throughput arrays to screen 
viruses, bacteria and other exogenous antigen sources, may provide needed insight into 
antigen specificity.
Relevance to current MS therapeutics
The CNS immune response in MS, particularly that of B cells, has been considered to be 
sequestered. Specifically, it has not been clear whether the B cell activity in the MS CNS is 
independent of that in the periphery, particularly the lymph nodes. This raised the question 
as to how therapeutics that may be limited to acting peripherally can affect changes in the 
CNS. Our findings, along with a recent study showing that CSF B cells exchange with the 
periphery (15), suggest that treatments affecting B cells in the periphery, have consequences 
for those that populate the CNS. B cell depletion (anti-CD20; rituximab, ocrelizumab, 
ofatumumab) is among the most effective MS therapies and these findings describe how it 
may impact the CNS.
Natalizumab is a monoclonal antibody that blocks immune cell migration into the CNS. 
Increased peripheral B cell frequencies observed post treatment suggest that natalizumab 
perturbs homing and migration through secondary lymphoid tissue (41). MS patients treated 
with natalizumab show a decrease in CD4+ T cells in the CSF and a subset of patients has 
diminished OCB (42, 43). A subset of those responding favorably to the treatment has 
reduced CSF immunoglobulin and B cells (44). These studies suggest that in some patients 
the immunoglobulin and OCB are dependent on B cells trafficking from the periphery while 
in others long-lived B cells that reside in a CNS niche may produce the OCB. Collectively, 
studies of natalizumab and our findings described here, along with investigations describing 
an overlap between CSF and peripherally circulating B cells indicate that B cells in the 
peripheral blood, lymph nodes and CNS traffic between these compartments. These findings 
clarify how peripherally acting therapeutics, such as natalizumab, may disrupt the B cell 
mediated immune response in the CNS.
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Materials and Methods
Study Design
This study was designed to determine whether B cells, known to populate the MS CNS, 
matured in the peripheral lymphoid tissue. Matched tissue specimens from MS CNS and 
draining CLNs were collected from five different MS autopsies. The core of the 
investigative approach was the comparison of the B cell repertoire between the CNS and 
peripheral lymphoid tissue from the same autopsy. We explored these antibody repertoires 
to (1) determine whether clonally expanded B cells that populate the CNS are related to B 
cells in the peripheral lymphoid tissue, (2) determine whether B cells traffic between the 
periphery and the CNS, (3) describe the traffic direction, and (4) ascertain the 
compartment(s) in which B cells experience affinity maturation. This study did not require 
blinding or randomization as neither would have provided an advantage for the 
interpretation or analysis of the data. Sanger sequencing was first used to establish whether 
members of B cell clonal families residing in the CNS were also present in a matched 
draining CLN. Then next generation sequencing was used to construct B cell antibody 
repertoires so that deeper analysis could be carried out to define how members of clones 
were represented in the CNS and periphery and how they trafficked between these two 
compartments. Repertoires were built from separated sections of the same tissue specimen 
so that identical members of expanded B cell clones could be identified. Sequencing error, 
inherent to the high throughput platform, and primary amplification bias were both greatly 
reduced by use of molecular bar codes that uniquely identified each mRNA molecule 
thereby affording the generation of a consensus sequence representing a B cell clone 
member. The analysis first probed whether members of clones, identified by common 
IGHV/J gene usage and similarity in their CDR3 sequence, could be identified in both the 
periphery and CNS to ascertain whether B cells were exclusive to either compartment. 
Lineage trees were constructed for clones that spanned the periphery and CNS to provide 
information on B cell trafficking patterns. A permutation-based method was applied to test 
hypotheses on the most likely location of the founding cells for these clones, and on the 
migration patterns of the cells over the course of clonal expansion.
High-throughput repertoire sequence analysis
Detailed methods for raw read processing, clonal assignment, diversity analysis, and lineage 
reconstruction can be found in Supplementary Materials. Briefly, raw high-throughput 
sequencing reads were quality controlled, assembled and filtered using pRESTO (45). V(D)J 
germline segments were determined using IMGT/HighV-QUEST (46). Functional V(D)J 
sequences were assigned into clonal groups on the basis of identical IGHV gene, IGHJ gene, 
and junction length, with a weighted interclonal distance threshold of 3 using the 
substitution probabilities previously described (47). Repertoire diversity was characterized 
using the Hill diversity index (48) with uniform resampling to correct for sequencing depth. 
Lineage trees were inferred via maximum parsimony with PHYLIP (49). The analysis of 
lineage tree topologies was performed using standard graph traversal algorithms provided by 
the igraph R package (50).
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Statistical Analyses
Confidence intervals for IGHV/J family and gene usage were estimated using the Wald 
method for log-odds ratios. Statistical significance of edge relationships and founder 
occurrence for lineage tree topologies was performed via permutation tests. Combined 
(meta-analysis) p-values were calculated using Stouffer’s method.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. B cell antibody repertoire sequencing demonstrates that clonally expanding B cells 
populate the MS CNS and draining CLNs
(A) Heat maps showing the sequence overlap between compartments. The number of unique 
IgG (upper left triangles) and IgM (lower right triangles) sequences that were shared 
between each pair of tissue compartments in subjects M5, M2 and M3 is displayed. 
Percentages are calculated as a fraction of sequences from the tissue with the lower number. 
Values on the transecting axis indicate the total number of distinct sequences collected from 
each tissue. (B) Column graphs showing how members of clones were distributed between 
the CNS and CLN. For each IgG (upper y-axis) and IgM (lower y-axis) clone with at least 
one member found in the CNS, the fraction of distinct mRNA sequences that reside in the 
CLN is shown.
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Fig. 2. The antibody repertoire in the CNS and CLN share features
Usage of both (A) IGHV families and (B) IGHJ genes were compared between the CNS and 
CLN. For each subject, the odds ratio (log) was calculated by measuring the distribution of 
the IGHV families in the CNS and normalizing it by the distribution in the periphery for the 
same subject. Positive values indicate that the observed segment usage is greater in the CNS 
and negative values indicate greater usage in the periphery. (C) The Hill diversity index 
(qD), which measures diversity in a population, was calculated for the set of IgG clones 
present in the CNS (solid black line curves) and CLN (dotted curves) to determine whether 
the diversity in the repertoires differed between the compartments. For each subject (shown 
in different panels), the repertoire was sub-sampled to the number of sequences in the 
smallest sample and the Hill diversity index was calculated independently in 1,000 equally 
spaced q values between 0 and 15. As q varies from 0 to infinity the diversity (qD) depends 
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less on rare species and more on common ones, thus encompassing a range of definitions 
that can be visualized as a single curve. For q=0, the diversity is defined as the total number 
of clones, while as q approaches infinity the diversity is given by one over the frequency of 
the largest clone. At a given value of q (x-axis), lower values of qD (y-axis) indicate lower 
diversity. The gray bands indicate the middle 95% percentiles of the sampled distribution, 
thus when both lines are separated and fall outside of the gray band the difference between 
the two is significant. The analysis shows that the CNS repertoire had lower qD values than 
those in the CLN demonstrating lower diversity in the CNS (i.e., a more focused repertoire).
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Fig. 3. Multi-compartment lineage trees illustrate that B cells traffic between the CLN and CNS
Representative lineage trees are shown for subject M2 (A), M3 (B) and M5 (C–F). Lineage 
trees are shown with the germline sequence at the root (black square). The number of 
somatic mutations accumulated from one node to the next is shown on each edge (branch) of 
the tree; an unlabeled edge corresponds to either 1 mutation (solid line) or 0 mutations 
(dotted line). Observed unique B cell sequences (nodes of the tree) are each annotated with 
text representing the tissue in which they were observed. The size (area) of each node is 
proportional to the number of unique mRNA sequences (number of UIDs) identified with 
the same nucleotide sequence.
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Fig. 4. Trafficking between CNS compartments and the CLN often occurs early in clonal 
expansion
Sequences were classified according to where they resided; CNS, CLN or CLN/CNS (multi-
compartment) and lineage trees were constructed for all clones that contained at least one 
CNS or multi-compartment sequence. Two separate analyses demonstrate that multi-
compartment B cells are more often observed as ancestors than those that resided in a single 
compartment. (A) For each lineage, the fraction of somatic mutation events accumulated by 
progeny of CNS, CLN or multi-compartment sequences was determined. The distribution 
over all lineages, along with the mean fraction (black horizontal bar), is shown as a violin 
plot for each subject. Increasing values on the Y-axis represents the propensity of a clonal 
family member to produce offspring. The width of the plot for the CNS, CLN or multi-
compartment sequences is proportional to the fraction of clonal members that produced 
descendants. A column that is wide only on the bottom indicates that few ancestors were 
among the clones. A column that is wide through its height indicates that many of the clonal 
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members were ancestral as they produced further ancestors. (B) The set of all expanded (>10 
unique sequences) multi-compartment lineage trees from each subject was analyzed to 
identify direct parent-child relationships among sequences from different compartments 
(numbers in each box). Statistically significant relationships, determined through 
permutation of node compartment labels (n=2000), are indicated in bold text. Numbers in 
parentheses indicate the effect strength, defined as the base 2 logarithm of the number of 
observed over the number of expected edges (branch in a lineage tree) of each type. These 
values designate whether the observation is more than (positive) or less than (negative) 
expected. Each edge type is shaded according to this effect strength, with darker colors 
indicating more edges (branches) than expected. Thus, the positive effect strength values 
observed only in the cases in which the parent node resided in two compartments indicates 
that these shared sequences more often gave rise to daughters than those restricted to a 
single compartment.
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Fig. 5. Proposed model of B cell maturation and migration observed between the CLN and CNS
A reconstruction of an immunoglobulin lineage from a hypothetical clone is shown on both 
sides of the blood brain barrier (BBB). GL refers to germline cells and letters refer to 
different antibody sequences (clonal variants represented as nodes) in a single clonal family. 
Empty nodes represent sequences that are not empirically observed in a particular 
compartment. Mature clonally expanded (IgM, IgG or IgA) B cells traffic between the CLN 
and the CNS compartments by crossing the BBB indicated by the dashed arrow. Cells 
originate (node GL) and clonally expand (node A) in the CLN before trafficking into the 
CNS. However, this process begins early in the clonal expansion process as less mature 
offspring (e.g. node C and H) from the CLN can reside in the CNS. Several possibilities 
exist where the B cells can migrate back and forth through the BBB. The proposed scenario 
suggests that periphery B cell clones migrate from the CLN to the CNS while undergoing 
additional clonal expansion. Clonally expanded (IgM, IgG and/or IgA) B cells within the 
CNS can then traffic back into the peripheral tissue and undergo additional clonal 
expansion.
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Table 1
Subject demographics and cellular characteristics of the CNS tissue.
Subject Disease state Age Gender Histopathologic findings
M1 Relapsing remitting MS 39 M Normal appearing white matter.
M2 Secondary progressive MS 53 F Small chronic periventricular white matter lesion without both perivascular 
infiltrations and microglial activation.
M3 Primary progressive MS 74 F Small chronic white matter lesion with perivascular infiltrates and microglial 
activation.
M4 Chronic progressive MS 80 M Small chronic periventricular white matter lesion without both perivascular 
infiltrations and microglial activation.
M5 Chronic MS 63 F Large chronic white matter lesion with occasional minimal perivascular infiltrates. 
No microglial activation.
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Table 2
Distribution of B cells belonging to clone.
Subject Isotype Tissue compartment Total sequences B cells belonging to a clone (%)
M2 IgHA CLN 15235 49
IgHA CNS 159 40
IgHG CLN 24478 60
IgHG CNS 1434 54
IgHM CLN 54896 13
IgHM CNS 108 45
M3 IgHA CLN 9605 82
IgHA CNS 285 32
IgHG CLN 48023 94
IgHG CNS 7803 95
IgHM CLN 11704 61
IgHM CNS 237 7
M4 IgHA CLN 11598 75
IgHA CNS 1 0
IgHG CLN 71709 89
IgHG CNS 28 21
IgHM CLN 20125 48
IgHM CNS 9 22
M5 IgHA CLN 17072 74
IgHA CNS 1534 77
IgHG CLN 190980 89
IgHG CNS 7219 71
IgHM CLN 8896 55
IgHM CNS 435 52
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